Full-Time

Vice President of Clinical Operations

Treeline Biosciences

Treeline Biosciences

51-200 employees

Biotech firm discovering cancer therapies.

Compensation Overview

$319.3k - $375.7k/yr

Belmont, MA, USA

In Person

Category
Biology & Biotech (1)
Required Skills
Google Cloud Platform
Requirements
  • Bachelor’s degree (BA/BS) in a relevant scientific field (e.g. nursing, biology, biochemistry, or related areas); advanced degree preferred.
  • At least 15 years of experience of successfully leading studies within clinical research operations.
  • Experience in Phase I-III oncology clinical studies. Global experience preferred.
  • Demonstrated expertise building and managing clinical operations teams.
  • Excellent verbal and written skills, allowing for an open and effective dialogue throughout the company.
  • Highly accountable for the results and outcomes of their responsibilities and understands the impact of their efforts, results, and attitudes on others.
  • Experience with agency submissions and inspections, understands adherence to SOPs, ICH/GCP, and FDA and other health authorities’ regulations.
  • Forward thinking mindset with ability to manage multiple projects, identify and resolve issues.
  • Strong analytical, organizational, and time management skills with a track record of identifying and implementing novel solutions and problem-solving.
  • Demonstrated agility and ability to navigate and be successful in a fast-paced, dynamic work environment.
  • Proven hands-on leadership and communication skills (written and verbal).
  • Team player who collaborates effectively with internal stakeholders as well as external contract organizations.
  • Be a champion of a highly collaborative, transparent, data driven, “make it happen” culture.
Responsibilities
  • Develop and lead a team of clinical operations professionals to ensure high-quality execution of early and late phase clinical trials and the professional development of team members.
  • Serve as subject matter expert in clinical operations, providing guidance and expertise to cross-functional teams, including clinical development, regulatory affairs, and data management.
  • Provide operational expertise and strategic input to Clinical Development Plans and support the overall clinical strategy for clinical programs.
  • Proactively communicate study plans, progress, risks and mitigations with senior leaders.
  • Develop, implement, and modify when needed a successful resource and outsourcing model to meet the evolving demands of an expanding clinical portfolio.
  • Manage study site selection, qualification, initiation, and monitoring activities to ensure that clinical trials are conducted according to the study protocol and in compliance with regulatory requirements.
  • Evaluate and negotiate budgets, oversee selection and provide oversight and management of CROs, consultants and vendors to ensure the effective and timely execution of clinical trials, with high quality (including inspection ready) and within agreed budget.
  • Monitor progress of clinical activity and report on the progress of clinical trials including budget, timelines, enrollment, and data collection / review.
  • Participate in the creation, review, and finalization of clinical study-related documents such as protocols, protocol amendments, clinical study reports (CSRs), regulatory submissions and other publications as required.
  • Coordinate the delivery of clinical trial supplies in collaboration with CRO and other company team members.
  • Develop and maintain strong relationships with clinical investigators and study site staff to ensure site performance, patient enrollment, and data quality; perform periodic visits to sites and/or vendors to assess progress and compliance.
  • Ensure clinical trials maintain an inspection readiness state throughout the lifecycle of the trial and provide subject matter expertise for regulatory inspections.
  • Maintain knowledge across the clinical operations team of program specific therapeutic areas, current medical practice, and pharmaceutical regulations in order to ensure best practice across all activities and appropriate communication to study sites.
  • Proactively implement process improvements and innovative approaches. Support the creation of clinical operations Standard Operating Procedures (SOPs), systems, and processes across the trials; ensures compliance with regulatory and other applicable standards and guidelines.

Treeline Biosciences develops proprietary therapies for cancer and other serious diseases by conducting in-depth R&D across biology, chemistry, protein sciences, and computational science. Its product work involves discovering and optimizing drug candidates, then licensing these therapies to larger pharmaceutical companies or selling them to healthcare providers, with support from CRO collaborations to speed development. The company differentiates itself through a balanced mix of in-house research and external partnerships, a robust IP strategy, and a team that blends experienced biotech veterans with new talent, all backed by funding from KKR to scale operations. Its goal is to build a sustainable, long-term pipeline of treatments that can reach patients while expanding capabilities and partnerships in the biotech ecosystem.

Company Size

51-200

Company Stage

Series A

Total Funding

$1.1B

Headquarters

Stamford, Connecticut

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • $1.1B funding from KKR enables Phase 1 data readouts in 2026.
  • Three more programs enter IND-enabling studies post-2026 readouts.
  • TLN-254 licensed from Hengrui with conditional China approval accelerates validation.

What critics are saying

  • TLN-372 fails Phase 1 efficacy versus Revolution Medicines' sotorasib in 6-12 months.
  • FDA holds TLN-372 for cardiac toxicities within 3-6 months.
  • Cash burns out by 2028 without Phase 2 progress forcing asset sales.

What makes Treeline Biosciences unique

  • Treeline develops BCL6 degrader TLN-121 for lymphomas using protein degradation.
  • TLN-372 provides pan-KRAS inhibition across mutations unlike G12C-specific rivals.
  • In-house platform selects optimal modalities like degraders and ADCs per target.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Treeline Biosciences who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

-1%
Endpoints News
Sep 3rd, 2025
Josh Bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B

Josh bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B.

Business Wire
Sep 3rd, 2025
Treeline Biosciences Secures $200M, Starts Trials

Treeline Biosciences announced the start of Phase 1 trials for three programs: TLN-121 (BCL6 degrader) and TLN-254 (EZH2 inhibitor) for lymphoma, and TLN-372 (pan-KRAS inhibitor) for KRAS-mutated cancers. They also secured a $200 million Series A extension, totaling $1.1 billion in funding. CEO Josh Bilenker highlighted their aim to create a leading biopharma company with innovative cancer treatments.

VentureCapital.com
Sep 3rd, 2025
Treeline Biosciences Commences Phase 1 Trials and Secures $200 Million Series A Extension Funding

Treeline Biosciences commences Phase 1 trials and secures $200 million Series A extension funding.

VC News Daily
Jan 5th, 2025
Treeline Biosciences Raises $421M Funding

Treeline Biosciences, a drug discovery startup based in Watertown, MA, has secured $421 million in October's largest fundraising round.

The Business Journals
Dec 30th, 2024
Treeline Biosciences raises $421.8M in 2024

Treeline Biosciences, based in Watertown, raised the largest venture capital round by a Massachusetts biotech in 2024, securing $422 million. Co-founded by Joshua Bilenker and Jeffrey Engelman, the company focuses on challenging molecular targets in oncology.